論文 - 詳細
| RRC ID | 65866 |
|---|---|
| 著者 | Fujii C, Miyashita K, Mitsuishi M, Sato M, Fujii K, Inoue H, Hagiwara A, Endo S, Uto A, Ryuzaki M, Nakajima M, Tanaka T, Tamaki M, Muraki A, Kawai T, Itoh H. |
| タイトル | Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid. |
| ジャーナル | Sci Rep |
| Abstract |
Recently, sarcopenia has attracted attention as therapeutic target because it constitutes a risk factor for metabolic and cardiovascular diseases. We focused 5-aminolevulinic acid (ALA) which act as electron carriers in the mitochondrial electron transport system. The mice that received ALA for 8 weeks gained muscle strength and endurance, and exhibited increased muscle mass and mitochondrial amount. Administration of ALA to sarcopenia mice aged 100 weeks and chronic kidney disease (CKD) model mice also increased muscle mass and improved physical performance. Metabolome analysis revealed increased branched-chain amino acids (BCAAs) levels in the skeletal muscle of ALA-treated mice. Quantitative PCR analysis revealed decreased expression levels in branched-chain amino acid transaminases (BCATs) that degrade BCAAs and other muscle-degrading factors, and increased levels of mitochondria-activating factors. We also studied in cultured myocytes and obtained compatible results. ALA-treated mice tended to increase body weight, but reduced blood glucose level. These suggested that ALA treatment not only activated muscle mitochondria but also enhanced muscle mass through an increase in BCAAs contents, as to improve muscle strength, endurance and glucose tolerance in mice. In these ways, muscle mitochondrial activation with ALA is suggested to be useful for the treatment of sarcopenia and glucose intolerance. |
| 巻・号 | 7(1) |
| ページ | 4013 |
| 公開日 | 2017-6-21 |
| DOI | 10.1038/s41598-017-03917-0 |
| PII | 10.1038/s41598-017-03917-0 |
| PMID | 28638045 |
| PMC | PMC5479778 |
| MeSH | Aminolevulinic Acid / administration & dosage* Animals Blood Glucose / drug effects Body Weight / drug effects Disease Models, Animal Electron Transport Complex I / genetics Glucose Intolerance / drug therapy* Glucose Intolerance / metabolism Glucose Intolerance / physiopathology Humans Mice Mitochondria, Muscle / drug effects Mitochondria, Muscle / metabolism Muscle Strength / drug effects* Muscle Strength / physiology Physical Endurance / drug effects Risk Factors Sarcopenia / drug therapy* Sarcopenia / metabolism Sarcopenia / physiopathology |
| IF | 3.998 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Youtube |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | C2C12(RCB0987) |